The Functional Neuroanatomy of Brain Cannabinoid Receptors
暂无分享,去创建一个
[1] H. Yamamura,et al. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. , 1997, European journal of pharmacology.
[2] C. Breivogel,et al. Regional differences in cannabinoid receptor/G-protein coupling in rat brain. , 1997, The Journal of pharmacology and experimental therapeutics.
[3] D. Piomelli,et al. A second endogenous cannabinoid that modulates long-term potentiation , 1997, Nature.
[4] M. Glass,et al. Concurrent Stimulation of Cannabinoid Cb1 and Dopamine D2 Receptors Augments Camp Accumulation in Striatal Neurons: Evidence for a G S Linkage to the Cb1 Receptor , 1997 .
[5] G. Di Chiara,et al. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. , 1997, Science.
[6] G. Koob,et al. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. , 1997, Science.
[7] A. Makriyannis,et al. Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics. , 1997, Biochemical pharmacology.
[8] L. Murphy,et al. Role of the hypothalamic-pituitary-adrenal axis in the suppression of luteinizing hormone release by delta-9-tetrahydrocannabinol. , 1997, Neuroendocrinology.
[9] R. Roth,et al. Δ9-Tetrahydrocannabinol Increases Prefrontal Cortical Catecholaminergic Utilization and Impairs Spatial Working Memory in the Rat: Blockade of Dopaminergic Effects with HA966 , 1997, Neuropsychopharmacology.
[10] G. Gessa,et al. Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A. , 1997, European journal of pharmacology.
[11] E. French. Δ 9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors , 1997, Neuroscience Letters.
[12] R. Quock,et al. delta 9-Tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain. , 1997, European journal of pharmacology.
[13] S. Gatley,et al. Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices. , 1997, European journal of pharmacology.
[14] J. Brotchie,et al. Paradoxical action of the cannabinoid WIN 55,212‐2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices , 1997, British journal of pharmacology.
[15] J. Walker,et al. Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. , 1997, Journal of neurophysiology.
[16] R. Faull,et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain , 1997, Neuroscience.
[17] R. Pertwee. Pharmacology of cannabinoid CB1 and CB2 receptors. , 1997, Pharmacology & therapeutics.
[18] E. Gardner,et al. The effect of intravenous administration of delta-9-tetrahydrocannabinol on the activity of A10 dopamine neurons recorded in vivo in anesthetized rats. , 1997, Neuropsychobiology.
[19] D. Selley,et al. mu-Opioid receptor-stimulated guanosine-5'-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. , 1997, Molecular pharmacology.
[20] R. Hampson,et al. Effects of Chronic Treatment with Δ9-Tetrahydrocannabinol on Cannabinoid-Stimulated [35S]GTPγS Autoradiography in Rat Brain , 1996, The Journal of Neuroscience.
[21] A. Hohmann,et al. Suppression of Noxious Stimulus-Evoked Activity in the Ventral Posterolateral Nucleus of the Thalamus by a Cannabinoid Agonist: Correlation between Electrophysiological and Antinociceptive Effects , 1996, The Journal of Neuroscience.
[22] J. Orsini,et al. Neuronal responses to Δ9-tetrahydrocannabinol in the solitary tract nucleus , 1996 .
[23] H. Rosenberg,et al. Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA , 1996, Brain Research.
[24] S. Childers,et al. Cannabinoid receptor stimulation of guanosine-5'-O-(3-[35S]thio)triphosphate binding in rat brain membranes. , 1996, Life sciences.
[25] J. Brotchie,et al. Activation of the cannabinoid receptor by Δ9-tetrahydrocannabinol reduces γ-aminobutyric acid uptake in the globus pallidus , 1996 .
[26] M. Shen,et al. Cannabinoid Receptor Agonists Inhibit Glutamatergic Synaptic Transmission in Rat Hippocampal Cultures , 1996, The Journal of Neuroscience.
[27] D. Selley,et al. Differences in G-protein activation by μ-and δ-opioid, and cannabinoid, receptors in rat striatum , 1996 .
[28] C. Ashby,et al. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. , 1996, The Journal of pharmacology and experimental therapeutics.
[29] J. Walker,et al. Electrophysiological effects of a cannabinoid on neural activity in the globus pallidus. , 1996, European journal of pharmacology.
[30] A. Buriani,et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[31] J. Brotchie,et al. Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212‐2 , 1996, Synapse.
[32] A. Lichtman,et al. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. , 1996, The Journal of pharmacology and experimental therapeutics.
[33] R. Knapp,et al. Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception , 1996, Neuroreport.
[34] K. Mackie,et al. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[35] J. Lowe,et al. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. , 1995, European journal of pharmacology.
[36] R. Hampson,et al. Cannabinoids selectively decrease paired-pulse facilitation of perforant path synaptic potentials in the dentate gyrus in vitro , 1995, Brain Research.
[37] D. Selley,et al. In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate binding. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[38] S. L. Patrick,et al. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. , 1995, European journal of pharmacology.
[39] R. Pertwee,et al. Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid‐mediated blockade of long‐term potentiation in the rat hippocampal slice , 1995, British journal of pharmacology.
[40] J. Walker,et al. Effects of a cannabinoid on spontaneous and evoked neuronal activity in the substantia nigra pars reticulata. , 1995, European journal of pharmacology.
[41] A. Hohmann,et al. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. , 1995, Life sciences.
[42] B. Martin,et al. Effects of anandamide (endogen cannabinoid) on anterior pituitary hormone secretion in adult ovariectomized rats. , 1995, Life sciences.
[43] A. Lichtman,et al. Evaluation of cAMP involvement in cannabinoid-induced antinociception. , 1995, Life sciences.
[44] S. L. Patrick,et al. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. , 1995, Life sciences.
[45] R. Hampson,et al. Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. , 1995, The Journal of pharmacology and experimental therapeutics.
[46] M. Kaghad,et al. An Amino-terminal Variant of the Central Cannabinoid Receptor Resulting from Alternative Splicing (*) , 1995, The Journal of Biological Chemistry.
[47] R. Mechoulam,et al. Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens , 1995, Neuropharmacology.
[48] P. Fan. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. , 1995, Journal of neurophysiology.
[49] S. Welch,et al. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. , 1995, The Journal of pharmacology and experimental therapeutics.
[50] A. Howlett,et al. Pharmacology of cannabinoid receptors. , 1995, Annual review of pharmacology and toxicology.
[51] L. Shaw,et al. Cannabinoids and appetite stimulation , 1994, Pharmacology Biochemistry and Behavior.
[52] P. Soubrié,et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor , 1994, FEBS letters.
[53] R. Pertwee,et al. The action of synthetic cannabinoids on the induction of long-term potentiation in the rat hippocampal slice. , 1994, European journal of pharmacology.
[54] S. Childers,et al. Effects of anandamide on cannabinoid receptors in rat brain membranes. , 1994, Biochemical pharmacology.
[55] S. L. Patrick,et al. Antinociceptive actions of cannabinoids following intraventricular administration in rats , 1993, Brain Research.
[56] E. Gardner,et al. Ventral tegmental microinjection of Δ9-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana's psychoactive ingredient , 1993, Brain Research.
[57] S. Munro,et al. Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.
[58] K. Mackie,et al. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. , 1993, Molecular pharmacology.
[59] S. Welch. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice. , 1993, The Journal of pharmacology and experimental therapeutics.
[60] K. Rice,et al. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. , 1993, The Journal of pharmacology and experimental therapeutics.
[61] S. Childers,et al. Identification of cannabinoid receptors in cultures of rat cerebellar granule cells , 1993, Brain Research.
[62] T. Bliss,et al. A synaptic model of memory: long-term potentiation in the hippocampus , 1993, Nature.
[63] S A Deadwyler,et al. Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells. , 1993, The Journal of pharmacology and experimental therapeutics.
[64] D. Gibson,et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.
[65] N. Kaminski,et al. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. , 1992, Molecular pharmacology.
[66] J. Vanderhaeghen,et al. Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radioautography and in situ hybridization histochemistry , 1992, Neuroscience.
[67] K. Mackie,et al. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[68] B. Martin,et al. Spinal mechanisms ofΔ9-tetrahydrocannabinol-induced analgesia , 1992, Brain Research.
[69] D. Haycock,et al. Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles , 1992, Brain Research.
[70] S. C. Newton,et al. Evidence for a direct anterior pituitary site of delta-9-tetrahydrocannabinol action , 1991, Pharmacology Biochemistry and Behavior.
[71] A. Lichtman,et al. Spinal and supraspinal components of cannabinoid-induced antinociception. , 1991, The Journal of pharmacology and experimental therapeutics.
[72] M. Herkenham,et al. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat , 1991, Brain Research.
[73] S. Childers,et al. Aminoalkylindoles: actions on specific G-protein-linked receptors. , 1991, The Journal of pharmacology and experimental therapeutics.
[74] R. Pertwee,et al. Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids , 1991, Neuropharmacology.
[75] R. Steger,et al. Δ9-Tetrahydrocannabinol antagonism of the anterior pituitary response to estradiol in immature female rats , 1991, Steroids.
[76] M. Herkenham,et al. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[77] T. Bonner,et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.
[78] G. E. Alexander,et al. Functional architecture of basal ganglia circuits: neural substrates of parallel processing , 1990, Trends in Neurosciences.
[79] M. Herkenham,et al. Cannabinoid receptor localization in brain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[80] A. Bartke,et al. Effects of delta-9-tetrahydrocannabinol, cannabinol and cannabidiol, alone and in combinations, on luteinizing hormone and prolactin release and on hypothalamic neurotransmitters in the male rat. , 1990, Neuroendocrinology.
[81] Effects of delta-9-tetrahydrocannabinol on sensory evoked hippocampal activity in the rat: principal components analysis and sequential dependency. , 1989, The Journal of pharmacology and experimental therapeutics.
[82] A. Howlett,et al. Determination and characterization of a cannabinoid receptor in rat brain. , 1988, Molecular pharmacology.
[83] G. Di Chiara,et al. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[84] G. Snyder,et al. Hypothalamic action of delta-9-tetrahydrocannabinol to inhibit the release of prolactin and growth hormone in the rat. , 1988, Neuroendocrinology.
[85] R. Pertwee. The central neuropharmacology of psychotropic cannabinoids. , 1988, Pharmacology & therapeutics.
[86] T. Teyler,et al. The modulation of long-term potentiation by delta-9-tetrahydrocannabinol in the rat hippocampus, in vitro , 1987, Brain Research Bulletin.
[87] R. Hampson,et al. Effects of delta 9-tetrahydrocannabinol on sensory-evoked discharges of granule cells in the dentate gyrus of behaving rats. , 1986, The Journal of pharmacology and experimental therapeutics.
[88] R. Hampson,et al. delta 9-Tetrahydrocannabinol differentially affects sensory-evoked potentials in the rat dentate gyrus. , 1986, The Journal of pharmacology and experimental therapeutics.
[89] J. Brady,et al. Behavioral analysis of marijuana effects on food intake in humans , 1986, Pharmacology Biochemistry and Behavior.
[90] L E Hollister,et al. Health aspects of cannabis. , 1986, Pharmacological reviews.
[91] A. Howlett,et al. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. , 1986, Molecular pharmacology.
[92] L. Tyrey. Reversal of the delta-9-tetrahydrocannabinol inhibitory effect on prolactin secretion by rostral deafferentation of the medial basal hypothalamus. , 1986, Neuroendocrinology.
[93] L. Murphy,et al. Induction of luteinizing hormone release by electrochemical stimulation of the medial preoptic area in delta 9-tetrahydrocannabinol-blocked proestrous rats. , 1986, Neuroendocrinology.
[94] R. Harris,et al. Effects of the cannabinoids on physical properties of brain membranes and phospholipid vesicles: fluorescence studies. , 1985, The Journal of pharmacology and experimental therapeutics.
[95] A. Bloom,et al. The effects of δ9-tetrahydrocannabinol on serum thyrotropin levels in the rat , 1984, Pharmacology Biochemistry and Behavior.
[96] R. Steger,et al. Interactions of delta 9-tetrahydrocannabinol (THC) with hypothalamic neurotransmitters controlling luteinizing hormone and prolactin release. , 1983, Neuroendocrinology.
[97] A. Fitton,et al. CHANGES IN BODY TEMPERATURE AND OXYGEN CONSUMPTION RATE OF CONSCIOUS MICE PRODUCED BY INTRAHYPOTHALAMIC AND INTRACEREBROVENTRICULAR INJECTIONS OF Δ9‐TETRAHYDROCANNABINOL , 1982, British journal of pharmacology.
[98] C. Hughes,et al. Delta 9-tetrahydrocannabinol suppression of prolactin secretion in the rat: lack of direct pituitary effect. , 1981, Endocrinology.
[99] R. Steger,et al. The effects of delta 9-tetrahydrocannabinol on the positive and negative feedback control of luteinizing hormone release. , 1980, Life sciences.
[100] M. Hosko,et al. Hypothermic effects of intraventricular and intravenous administration of cannabinoids in intact and brainstem transected cats , 1980, Neuropharmacology.
[101] J. Dean,et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. , 1979, The New England journal of medicine.
[102] S. London,et al. Suppression of Cancer Chemotherapy-Induced Vomiting in the Cat by Nabilone, a Synthetic Cannabinoid 1 , 1979, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[103] A. Bartke,et al. Direct and pituitary-mediated effects of Δ 9-THC and cannabinol on the testis , 1978, Pharmacology Biochemistry and Behavior.
[104] L. Tyrey. delta-9-Tetrahydrocannabinol suppression of episodic luteinizing hormone secretion in the ovariectomized rat. , 1978, Endocrinology.
[105] I. Nir,et al. Acute effect of delta1-tetrahydrocannabinol on the hypothalamo-pituitary-ovarian axis in the rat. , 1977, Neuroendocrinology.
[106] S. Sallan,et al. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. , 1975, The New England journal of medicine.
[107] A. Sheth,et al. Effect of Acute Δ9-Tetrahydrocannabinol Treatment on Serum Luteinizing Hormone and Prolactin Levels in Adult Female Rats , 1975 .
[108] V. Houser. The effects of Δ9-tetrahydrocannabinol upon fear-motivated behavior in squirrel monkeys , 1975 .
[109] Joseph F. Garcia,et al. Effects of Δ9 - THC on growth hormone and ACTH secretion in rats , 1974 .
[110] I. Nir,et al. Suppression of the Cyclic Surge of Luteinizing Hormone Secretion and of Ovulation in the Rat by Δ1-Tetrahydrocannabinol , 1973, Nature.
[111] H. Barry,et al. Corticosterone elevation mediated centrally by Δ1-tetrahydrocannabinol in rats , 1971 .
[112] L. Harris,et al. The effect of 1-trans-delta 9-tetrahydrocannabinol on the hypothalamo-hypophyseal-adrenal axis of rats. , 1970, European journal of pharmacology.
[113] J. Jaffe,et al. 1-δ9-Tetrahydrocannabinol: Neurochemical and Behavioral Effects in the Mouse , 1969, Science.
[114] R. Mechoulam,et al. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish , 1964 .